USPTO serial 87488596
ZACOL
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICHELI, ANGELA M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ZACOL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Pickerill
JOHN PICKERILL FREDRIKSON & BYRON, P.A.200 S. 6TH STREETSUITE 4000MINNEAPOLIS, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for intestinal disorders; pharmaceutical preparations for use in gastroenterology, for the prevention and treatment of diarrhea, antibiotic-associated diarrhea, travellers' diarrhea, for colon and digestive system health and regulation, for improving energy levels, and for maintaining and improving mucous levels and the mucosal lining of the intestines and colon; pharmaceutical preparations for use in sanitary preparations for medical purposes, namely, nutraceutical preparations for colon and digestive system health and regulation, for maintenance and improvement of energy levels, and for maintaining and improving mucous levels and the mucosal lining of the intestines and colon; pharmaceutical preparations for stimulating the growth of intestinal flora, restoring energy and metabolism of the colocyte and rescuing of the colonic mucosal trophism; pharmaceutical preparations for the treatment of colon disorders; pharmaceutical preparations for improving epithelial vitality and repair; pharmaceutical preparations for the prevention or treatment of cancer; pharmaceutical preparations for the prevention or treatment of colorectal cancer; pharmaceutical preparations for restoring the metabolic balance; pharmaceutical preparations for improving the trophic conditions of the mucosa; pharmaceutical preparations for regulating human gut homeostasis; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical preparations for the treatment of inflammatory bowel disease, motility and functional disorders of the bowel such as IBS and colorectal tumours; pharmaceutical preparations for the maintenance of colon eubiosis; pharmaceutical preparations for decreasing intestinal inflammation; pharmaceutical preparations for promoting, supporting and maintaining a healthy colon; pharmaceutical preparations for the treatment of colitis, ulcerative colitis, Crohn's disease, radiation colitis, pouchitis, infectious colitis and shigellosis; pharmaceutical preparations for the treatment of polyposis of the colon; pharmaceutical preparations for the treatment of pain; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical and veterinary preparations in the form of tablets, capsules, sugar-coated pills, granules, powders or suppositories for the treatment of gastrointestinal disease and conditions; Pharmaceutical preparations, namely, anti-flatulars; sanitary preparations for medical purposes; Dietetic foods adapted for medical use; Dietetic foods and beverages adapted for medical use; pharmaceutical preparations for the treatment of intestinal infections; pharmaceutical preparations used to treat gastro-intestinal diseases and conditions; Diagnostic agents, preparations and substances related to the gastro-intestinal field for medical purposes; medical preparations based on butyric acid and inulin that contributes to the restoration of intestinal barrier; lactic ferments for pharmaceutical use; biological preparations for use in the gastrointestinal diseases and conditions; food supplements; dietary supplements; vitamin supplements; nutritional supplements; dietary supplemental drinks; vitamin preparations in the form of food supplements; nutraceutical products for use as dietary supplements; Nutraceutical preparations for therapeutic or medical purposes; Mineral supplements for human use | ACTIVE | — |
| 010 | Medical apparatus for introducing pharmaceutical preparations, food supplements and nutraceuticals into the human body; Medical apparatus for introducing pharmaceutical preparations food supplements and nutraceuticals into the colon; Enema apparatus; Enema syringes; Enema apparatus for medical purposes; Rectal medical instruments for examination purposes; Medical apparatus for introducing enema preparations into the human body; Injection syringes; Syringes for medical purposes; Surgical devices and instruments; Disposable syringes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cosmo Technologies, Ltd.
- Other trademarks owned by Cosmo Technologies, Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named ZACOL
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 5, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 5, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 14, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 12, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 12, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 12, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 12, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 3, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 8, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 8, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 18, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 3, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 21, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 21, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 21, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 17, 2017 | NWAP | NEW APPLICATION ENTERED | — |